INNATE PHARMA SP.ADR/1 Cash Flow-to-Debt Ratio
INNATE PHARMA SP.ADR/1 cash flow-to-debt ratio. INNATE PHARMA SP.ADR/1 (IDDA) has a Cash Flow-to-Debt Ratio of -0.39x as of December 2025, meaning its operating cash flow of €-32.56 Million could theoretically repay 0% of its total liabilities (€84.42 Million) in one year. See INNATE PHARMA SP.ADR/1 (IDDA) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of INNATE PHARMA SP.ADR/1 (2021–2025)
Cash flow-to-debt ratio of INNATE PHARMA SP.ADR/1 from 2021 to 2025. Historical debt coverage capacity for INNATE PHARMA SP.ADR/1 across 5 annual periods. Also explore INNATE PHARMA SP.ADR/1 (IDDA) net asset momentum to track the company's year-over-year net asset growth rate.
INNATE PHARMA SP.ADR/1 Cash Flow-to-Debt Ratio by Year (2021–2025)
INNATE PHARMA SP.ADR/1 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for INNATE PHARMA SP.ADR/1. For the full cash flow conversion analysis, see INNATE PHARMA SP.ADR/1 (IDDA) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.39x | €-32.56 Million | €84.42 Million | ▼ -471.7% |
| 2024 | -0.07x | €-6.90 Million | €102.22 Million | ▲ +74.5% |
| 2023 | -0.26x | €-32.56 Million | €123.29 Million | ▼ -100.1% |
| 2022 | -0.13x | €-19.16 Million | €145.14 Million | ▲ +63.9% |
| 2021 | -0.37x | €-58.46 Million | €160.06 Million | — |